RecruitingOBSERVATIONAL

GRASS (Grass MATA MPL Real-world Assessment Study)

This study, called GRASS, is observing how a medicine called Grassmuno® is used by patients with grass pollen allergy in their regular doctor's appointments. It's not testing a new medicine, but rather collecting information on how the existing medicine is used in real life. Doctors will decide which patients can take part, but generally, it's for adults aged 18 and over who are already receiving Grassmuno® for their hay fever or eye allergies caused by grass pollen. This applies if they have moderate to severe symptoms that affect their nose and/or eyes, with or without well-controlled asthma. The study aims to gather practical information about how the treatment is used outside of strict clinical trial settings.

At a glance

Status

Recruiting

Sponsor

Allergy Therapeutics

Enrolment target

1,000

Start

11 Mar 2026

Estimated completion

02 Oct 2028

Grass Pollen Allergy

What is this study about?

This study, known as GRASS, is all about understanding how a medicine called Grassmuno® is used by people in their normal daily lives when they have a grass pollen allergy. You might know grass pollen allergy better as hay fever that happens when grass is in bloom, often causing sneezing, a runny nose, and itchy, watery eyes.

Unlike studies that test if a new medicine works, this one is looking at an existing medicine that doctors are already prescribing. The researchers want to see how Grassmuno® is used in real-world situations, rather than under very strict, controlled conditions. They will collect information about how doctors are prescribing it and how patients are using it as part of their regular care.

The main goal is to get a clearer picture of how Grassmuno® fits into everyday treatment for grass pollen allergy. This helps medical professionals understand the experience of patients and doctors better, which can lead to better advice and support for people with this type of allergy in the future.

Key takeaways

This study observes how an existing grass allergy medicine (Grassmuno®) is used in regular care.
It's for adults (18+) already prescribed Grassmuno® for hay fever or eye allergies caused by grass pollen.
No new treatments or extra doctor visits are involved; it records your usual treatment.
Your doctor decides if you are suitable based on your current health and treatment.
Participation helps gather important information to improve understanding of real-world treatment.
You can stop being part of the study whenever you want to.

Who may be eligible?

To be able to join this study, a doctor needs to decide if it's right for you. Generally, you would need to be an adult, 18 years old or older. You should also already be receiving treatment with Grassmuno® for your grass pollen allergy, specifically if it causes moderate to severe hay fever or itchy, watery eyes (rhinitis and conjunctivitis). It's okay if you also have asthma, as long as your asthma is well-controlled.

Important: You won't be considered for the study until your doctor has already decided that Grassmuno® is the right treatment for you. This study doesn't influence that treatment decision.

There are also some reasons why you might not be able to join. For example, if you don't understand German well enough to read the study documents, you wouldn't be able to participate. Also, if there are any reasons listed in the official medicine information (called the Summary of Product Characteristics, or SmPC) that mean you shouldn't take Grassmuno® at all, then you wouldn't be able to join the study either.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Are you currently receiving Grassmuno® for your grass pollen allergy (hay fever or eye allergies)?
Did your doctor already decide that Grassmuno® is the right treatment for you?
Do you understand English well enough to read information about the study?
Are there no medical reasons listed in the Grassmuno® information that mean you shouldn't take it?
Is your asthma, if you have it, well-controlled?

Answer every question to see your result.

What does participation involve?

If you join this study, you won't be asked to do anything extra regarding your treatment. You'll continue to receive your Grassmuno® as prescribed by your doctor, just as you would normally. The study is about observing your regular treatment. This means there will be no additional visits to the clinic apart from your usual appointments. Your doctor will simply collect some information about your health and how you're using Grassmuno® during your routine check-ups. There are no new medications to take or special tests. The total duration of your participation will depend on how long your doctor typically monitors your Grassmuno® treatment, but it will fit into your usual care schedule.

Potential risks and benefits

Since this study is simply observing your routine care with a medicine you are already receiving, there are no additional medical risks beyond those typically associated with Grassmuno®, which your doctor would have discussed with you. You won't be given any new or experimental treatments. The main benefit of participating is that the information collected about your experience can help doctors and researchers understand more about how Grassmuno® works for people in real life, potentially improving treatment for others with grass pollen allergy in the future. You always have the right to withdraw from the study at any time without affecting your medical care.

Locations (1)

Dr. Kasche
Verified postcode
Hamburg, Germany· Recruiting

Common questions

What is the main purpose of this study?

The study aims to observe how a medicine called Grassmuno® is used by patients with grass pollen allergy in their regular doctor's visits, to gather real-world information.

Will I take a new or experimental medicine?

No, you will only be observed while taking Grassmuno®, which is an existing medicine your doctor has already prescribed for you.

Do I need extra doctor appointments for this study?

No, you will only attend your regular, existing appointments. No additional visits are required for the study itself.

Can I leave the study if I change my mind?

Yes, you can choose to leave the study at any time without it affecting your medical care or relationship with your doctor.

Who can join the study?

Generally, adults aged 18 or over who are currently being treated with Grassmuno® for grass pollen allergy (hay fever or eye allergy) and whose doctor thinks it's suitable.

How to find out more

Ralph Mösges, Univ. Prof. Dr. med. Dipl.-Ing

ralph.moesges@uni-koeln.de +49 172 2056 230 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.